Analyst firms · Leerink Partners · PRCT
Leerink Partners PRCT price target and rating history
PROCEPT BioRobotics Corporation (PRCT) · Health Care
Leerink Partners rates PROCEPT BioRobotics Corporation (PRCT) Market Perform with a $29 price target, as of its latest action on Jun 11, 2026. It has published 4 rating actions on PRCT since October 2021, including 0 upgrades and 1 downgrade. Across 8 firms with a PRCT price target in the last 12 months, the median target is $27. Leerink Partners's $29 is 7% above that.
- Current rating
- Market Perform
- Price target
- $29
- Median target, all firms
- $27
- Actions on PRCT
- 4
Leerink Partners price target on PRCT
Every Leerink Partners rating on PRCT
- Jun 11, 2026
- Mar 9, 2022
- Nov 5, 2021
- Oct 11, 2021
How other firms rate PRCT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $30 | Oct 7, 2026 |
| William Blair | Mkt Perform | Aug 5, 2026 | |
| Wells Fargo | Equal Weight | $19 | Aug 5, 2026 |
| UBS | Neutral | $20 | Jul 28, 2026 |
| Truist Securities | Hold | $25 | Jul 6, 2026 |
| Evercore ISI | Outperform | $30 | Jun 24, 2026 |
| Leerink Partners | Market Perform | $29 | Jun 11, 2026 |
| Robert W. Baird | Neutral | $30 | Mar 6, 2026 |
| Oppenheimer | Perform | Feb 26, 2026 | |
| BofA Securities | Underperform | $20 | Feb 26, 2026 |
Questions about Leerink Partners and PRCT
- What is Leerink Partners's price target for PRCT?
- Leerink Partners's latest stated price target for PROCEPT BioRobotics Corporation (PRCT) is $29, from its action on Jun 11, 2026.
- What is Leerink Partners's rating on PRCT?
- Leerink Partners rates PRCT Market Perform, a neutral rating, as of Jun 11, 2026.
- When did Leerink Partners last change its view on PRCT?
- On Jun 11, 2026, Leerink Partners downgrades to Market Perform from Outperform, price target $29.
- How does Leerink Partners's PRCT target compare with other analysts?
- Across 8 firms with a PRCT price target in the last 12 months, the median target is $27. Leerink Partners's $29 is 7% above that.
More PRCT rating histories
All Leerink Partners ratingsPRCT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.